A New Drug Delivery System for Immuno and Chemotherapy Agents
- This topic has 2 replies, 2 voices, and was last updated 10 years, 6 months ago by
.
-
Posts
-
Hi, everyone,
http://www.ejcancer.com/article/S0959-8049(13)00543-1/abstract
The above talks about PD-1 and PD-L1 if interested.
God bless.
Hi, everyone,
If interest to you. check out their links too. My guess is that if this is just what they said is mainly a new drug delivery method or system (electroporation platform; similary to using albumin particles attached to the chemotherapy agent to form Abraxane– more or less like a guided missile system for paclitaxel,the chemotherapy agent),If this it is true for this new system;it may get FDA’s approval faster since most the research of the chemotherapy agents had been done and approved by FDA already.” OncoSec Medical’s core technology is based upon its proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.
Read more here: http://www.heraldonline.com/2013/10/08/5283839/oncosec-medical-announces-positive.html#storylink=cpy
God bless.
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.